Shares of Sarepta Therapeutics Inc. (ticker: SRPT) experienced two trading halts on July 24, 2025, amid uncertainty over news developments. Earlier that day, Citi initiated coverage of Sarepta with a Sell rating and set a price target of $7, citing risks including potential withdrawal of the gene therapy Elevidys and concerns over liver-related deaths. Following the halts, shares initially spiked after resuming trading. A senior FDA official indicated that Sarepta might address liver safety concerns by adjusting dosing or manufacturing processes and conducting tests in a small group of 10 to 12 boys, rather than undertaking full new studies as previously suggested. This update led to a rebound in Sarepta's share price, which rose to $13.34. The FDA discussions and the possibility of a softer regulatory approach on Elevidys appear to have influenced the market reaction.
$SRPT we got all the info now! https://t.co/uEA6mBPmao
Just in: $SRPT shares rebound as Endpoints News updates on FDA discussions. A senior official suggests Sarepta could adjust dosing or manufacturing for Elevidys to address liver issues. Shares up to $13.34.
Sarepta $SRPT shares spiked off lows after a senior official said the company could adjust dosing or manufacturing and test in a small group (10–12 boys) to address liver safety issues — a softer stance than earlier reports suggesting full new studies would be required.